Current trends in West Nile virus vaccine development

Expert Review of Vaccines

Volumn 13, Issue 5, 2014, Pages 589-608

  Amanna, Ian J ^a   Slifka, Mark K ^b  

^a Najít Technologies Inc ^*  (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

antibody; epidemiology; flaviviruses; immunity; immunocompromised; neurotropic; vaccination; West Nile virus

Indexed keywords

CHIMERAVAX WN 02; DNA VACCINE; EQUILIS; INACTIVATED VACCINE; LIVE VACCINE; RECOMBINANT VACCINE; SUBUNIT VACCINE; UNCLASSIFIED DRUG; WEST NILE VACCINE; WNV 80E;

CLINICAL TRIAL (TOPIC); COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG SAFETY; FATALITY; HEALTH CARE COST; HORSE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFECTION PREVENTION; INJECTION SITE REACTION; MASS IMMUNIZATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; UNITED STATES; VIRUS IMMUNITY; WEST NILE FLAVIVIRUS; ANIMAL; DRUG EFFECTS; PREVENTIVE HEALTH SERVICE; PROCEDURES; TRENDS; WEST NILE FEVER;

ANIMALS; HUMANS; IMMUNIZATION PROGRAMS; WEST NILE FEVER; WEST NILE VIRUS; WEST NILE VIRUS VACCINES;

EID: 84905450095     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.2014.906309     Document Type: Review

References (175)

1. Go YY, Balasuriya UB, Lee CK. Zoonotic encephalitides caused by arboviruses: Transmission and epidemiology of alphaviruses and flaviviruses. Clin Exp Vaccine Res 2014;3(1):58-77
2. Roehrig JT. West nile virus in the United States-A historical perspective. Viruses 2013;5(12):3088-108
3. Kramer LD, Styer LM, Ebel GD. A global perspective on the epidemiology of West Nile virus. Annu Rev Entomol 2008;53: 61-81
4. Lanciotti RS, Roehrig JT, Deubel V, et al. Origin of the West Nile virus responsible for an outbreak of encephalitis in the northeastern United States. Science 1999; 286(5448):2333-7
5. Pinto AK, Richner JM, Poore EA, et al. A Hydrogen Peroxide-Inactivated Virus Vaccine Elicits Humoral and Cellular Immunity and Protects against Lethal West Nile Virus Infection in Aged Mice. J Virol 2013;87(4):1926-36
6. Sitati EM, Diamond MS. CD4+ T-cell responses are required for clearance of West Nile virus from the central nervous system. J Virol 2006;80(24):12060-9
7. Shrestha B, Ng T, Chu HJ, et al. The relative contribution of antibody and CD8 (+) T cells to vaccine immunity against West Nile encephalitis virus. Vaccine 2008; 26(16):2020-33
8. Netland J, Bevan MJ. CD8 and CD4 T cells in west nile virus immunity and pathogenesis. Viruses 2013;5(10):2573-84
9. Brien JD, Uhrlaub JL, Nikolich-Zugich J. Protective capacity and epitope specificity of CD8(+) T cells responding to lethal West Nile virus infection. Eur J Immunol 2007; 37(7):1855-63
10. Amanna IJ, Slifka MK. Wanted, dead or alive: New viral vaccines. Antiviral Res 2009; 84(2):119-30
11. Slifka MK. Vaccine-mediated immunity against dengue and the potential for long-Term protection against disease. Front Immunol 2014;In Press
12. Ben-Nathan D, Lustig S, Tam G, et al. Prophylactic and therapeutic efficacy of human intravenous immunoglobulin in treating West Nile virus infection in mice. J Infect Dis 2003;188(1):5-12
13. Oliphant T, Engle M, Nybakken GE, et al. Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nat Med 2005;11(5): 522-30
14. Engle MJ, Diamond MS. Antibody prophylaxis and therapy against West Nile virus infection in wild-Type and immunodeficient mice. J Virol 2003;77(24): 12941-9
15. Kreil TR, Eibl MM. Pre-And postexposure protection by passive immunoglobulin but no enhancement of infection with a flavivirus in a mouse model. J Virol 1997; 71(4):2921-7
16. Thibodeaux BA, Garbino NC, Liss NM, et al. A humanized IgG but not IgM antibody is effective in prophylaxis and therapy of yellow fever infection in an AG129/17D-204 peripheral challenge mouse model. Antiviral Res 2012;94(1):1-8
17. YF-VAX, package insert. Aventis Pasteur. Swiftwater, PA, USA; 2005
18. Mason RA, Tauraso NM, Spertzel RO, Ginn RK. Yellow fever vaccine: Direct challenge of monkeys given graded doses of 17D vaccine. Appl Microbiol 1973;25(4): 539-44
19. Belmusto-Worn VE, Sanchez JL, McCarthy K, et al. Randomized, double-blind, phase III, pivotal field trial of the comparative immunogenicity, safety, and tolerability of two yellow fever 17D vaccines (Arilvax and YF-VAX) in healthy infants and children in Peru. Am J Trop Med Hyg 2005;72(2):189-97
20. Monath TP, Nichols R, Archambault WT, et al. Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial. Am J Trop Med Hyg 2002;66(5): 533-41
21. IXIARO, package insert. Intercell-AG. Vienna 2013
22. Hombach J, Solomon T, Kurane I, et al. Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2-3 September, 2004. Vaccine 2005;23(45):5205-11
23. Orlinger KK, Hofmeister Y, Fritz R, et al. A tick-borne encephalitis virus vaccine based on the European prototype strain induces broadly reactive cross-neutralizing antibodies in humans. J Infect Dis 2011;203(11): 1556-64
24. Smithburn KC, Hughes TP, Burke AW, Paul JH. A neurotropic virus isolated from the blood of a native of Uganda. Am J Trop Med Hyg 1940;20:471-92
25. Hayes CG. West Nile virus: Uganda, 1937, to New York City, 1999. Ann NY Acad Sci 2001;951:25-37
26. Gubler DJ. The continuing spread of West Nile virus in the western hemisphere. Clin Infect Dis 2007;45(8):1039-46
27. Giladi M, Metzkor-Cotter E, Martin DA, et al. West Nile encephalitis in Israel, 1999: The New York connection. Emerg Infect Dis 2001;7(4):659-61
28. Mackenzie JS, Williams DT. The zoonotic flaviviruses of southern, south-eastern and eastern Asia, and Australasia: The potential for emergent viruses. Zoonoses Public Health 2009;56(6-7):338-56
29. Papa A, Politis C, Tsoukala A, et al. West Nile virus lineage 2 from blood donor, Greece. Emerg Infect Dis 2012;18(4):688-9
30. May FJ, Davis CT, Tesh RB, Barrett AD. Phylogeography of West Nile virus: From the cradle of evolution in Africa to Eurasia, Australia, and the Americas. J Virol 2011; 85(6):2964-74
31. Prow NA. The changing epidemiology of kunjin virus in australia. Int J Environ Res Public Health 2013;10(12):6255-72
32. Venter M, van Vuren PJ, Mentoor J, et al. Inactivated West Nile Virus (WNV) vaccine, Duvaxyn WNV, protects against a highly neuroinvasive lineage 2 WNV strain in mice. Vaccine 2013;31(37):3856-62
33. Minke JM, Siger L, Cupillard L, et al. Protection provided by a recombinant ALVAC((R))-WNV vaccine expressing the prM/E genes of a lineage 1 strain of WNV against a virulent challenge with a lineage 2 strain. Vaccine 2011;29(28):4608-12
34. CDC. 2014. WNV Statistics & Maps [Online]. CDC. Available from: Www.cdc. gov/westnile/statsMaps/[Last accessed 30 January 2014]
35. PHAC. 2013. Maps & Stats-West Nile virus-Public Health Agency of Canada [Online]. Available from: Www.phac-Aspc.gc. ca/wnv-vwn/index-eng.php [Last accessed 19 January 2014]
36. EPISOUTH. 2014. Network for Communicable Disease Control in Southern Europe and Mediterranean Countries [Online]. EpiSouth. Available from: Www. episouth.org/home.php [Last accessed 19 January 2014]
37. USGS. 2014. USGS West Nile Virus Maps [Online]. USGS. Available from: Http://diseasemaps.usgs.gov/wnv-historical.html [Last accessed 16 January 2014]
38. Carson PJ, Borchardt SM, Custer B, et al. Neuroinvasive disease and West Nile virus infection, North Dakota, USA, 1999-2008. Emerg Infect Dis 2012;18(4):684-6
39. Petersen LR, Carson PJ, Biggerstaff BJ, et al. Estimated cumulative incidence of West Nile virus infection in US adults, 1999-2010. Epidemiol Infect 2013;141(3): 591-5
40. Zohrabian A, Hayes EB, Petersen LR. Cost-effectiveness of West Nile virus vaccination. Emerg Infect Dis 2006;12(3): 375-80
41. Zou S, Foster GA, Dodd RY, et al. West Nile fever characteristics among viremic persons identified through blood donor screening. J Infect Dis 2010;202(9):1354-61
42. Mostashari F, Bunning ML, Kitsutani PT, et al Epidemic West Nile encephalitis, New York, 1999: Results of a household-based seroepidemiological survey. Lancet 2001; 358(9278):261-4
43. Hayes EB, Sejvar JJ, Zaki SR, et al. Virology, pathology, and clinical manifestations of West Nile virus disease. Emerg Infect Dis 2005;11(8):1174-9
44. Watson JT, Pertel PE, Jones RC, et al. Clinical characteristics and functional outcomes of West Nile Fever. Ann Intern Med 2004;141(5):360-5
45. Barzon L, Pacenti M, Franchin E, et al. Clinical and virological findings in the ongoing outbreak of West Nile virus Livenza strain in northern Italy, July to September 2012. Euro Surveill 2012;17(36): 20260
46. Hayes EB, Gubler DJ. West Nile virus: Epidemiology and clinical features of an emerging epidemic in the United States. Annu Rev Med 2006;57:181-94
47. Sejvar JJ, Haddad MB, Tierney BC, et al. Neurologic manifestations and outcome of West Nile virus infection. JAMA 2003; 290(4):511-15
48. Sejvar JJ, Leis AA, Stokic DS, et al. Acute flaccid paralysis and West Nile virus infection. Emerg Infect Dis 2003;9(7): 788-93
49. Jeha LE, Sila CA, Lederman RJ, et al. West Nile virus infection: A new acute paralytic illness. Neurology 2003;61(1):55-9
50. Li J, Loeb JA, Shy ME, et al. Asymmetric flaccid paralysis: A neuromuscular presentation of West Nile virus infection. Ann Neurol 2003;53(6):703-10
51. Sejvar JJ. The long-Term outcomes of human West Nile virus infection. Clin Infect Dis 2007;44(12):1617-24
52. Sejvar JJ, Bode AV, Marfin AA, et al. West Nile virus-Associated flaccid paralysis. Emerg Infect Dis 2005;11(7):1021-7
53. Lindsey NP, Staples JE, Lehman JA, Fischer M. Surveillance for human West Nile virus disease-United States, 1999-2008. MMWR Surveill Summ 2010; 59(2):1-17
54. Weber IB, Lindsey NP, Bunko-Patterson AM, et al. Completeness of West Nile virus testing in patients with meningitis and encephalitis during an outbreak in Arizona, USA. Epidemiol Infect 2012;140(9):1632-6
55. Emig M, Apple DJ. Severe West Nile virus disease in healthy adults. Clin Infect Dis 2004;38(2):289-92
56. Pepperell C, Rau N, Krajden S, et al West Nile virus infection in 2002. morbidity and mortality among patients admitted to hospital in southcentral Ontario. CMAJ 2003;168(11):1399-405
57. Voelker R. Effects of West nile virus may persist. JAMA 2008;299(18):2135-6
58. Green MS, Weinberger M, Ben-Ezer J, et al. Long-Term death rates, West Nile virus epidemic, Israel, 2000. Emerg Infect Dis 2005;11(11):1754-7
59. Barzon L, Pacenti M, Palu G. West Nile virus and kidney disease. Expert Rev Anti Infect Ther 2013;11(5):479-87
60. Tesh RB, Siirin M, Guzman H, et al. Persistent West Nile virus infection in the golden hamster: Studies on its mechanism and possible implications for other flavivirus infections. J Infect Dis 2005;192(2):287-95
61. Tonry JH, Xiao SY, Siirin M, et al. Persistent shedding of West Nile virus in urine of experimentally infected hamsters. Am J Trop Med Hyg 2005;72(3):320-4
62. Saxena V, Xie G, Li B, et al. A hamster-derived West Nile virus isolate induces persistent renal infection in mice. PLoS Negl Trop Dis 2013;7(6):e2275
63. Barzon L, Pacenti M, Franchin E, et al. Excretion of West Nile virus in urine during acute infection. J Infect Dis 2013; 208(7):1086-92
64. Murray K, Walker C, Herrington E, et al. Persistent infection with West Nile virus years after initial infection. J Infect Dis 2010;201(1):2-4
65. Gibney KB, Lanciotti RS, Sejvar JJ, et al. West nile virus RNA not detected in urine of 40 people tested 6 years after acute West Nile virus disease. J Infect Dis 2011;203(3): 344-7
66. Brener ZZ, Harbord NB, Zhuravenko I, et al. Acute renal failure in a patient with West Nile viral encephalitis. Nephrol Dial Transplant 2007;22(2):662-3
67. Huang C, Slater B, Rudd R, et al. First Isolation of West Nile virus from a patient with encephalitis in the United States. Emerg Infect Dis 2002;8(12):1367-71
68. Nolan MS, Podoll AS, Hause AM, et al. Prevalence of Chronic Kidney Disease and Progression of Disease Over Time among Patients Enrolled in the Houston West Nile Virus Cohort. PLoS ONE 2012;7(7): E40374
69. Lindsey NP, Sejvar JJ, Bode AV, et al Delayed mortality in a cohort of persons hospitalized with West Nile virus disease in Colorado in 2003. Vector Borne Zoonotic Dis 2012;12(3):230-5
70. Li L, Saade F, Petrovsky N. The future of human DNA vaccines. J Biotechnol 2012; 162(2-3):171-82
71. Davis BS, Chang GJ, Cropp B, et al. West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays. J Virol 2001;75(9):4040-7
72. Ishikawa T, Takasaki T, Kurane I, et al. Co-immunization with West Nile DNA and inactivated vaccines provides synergistic increases in their immunogenicities in mice. Microbes Infect 2007;9(9):1089-95
73. Anwar A, Chandrasekaran A, Ng ML, et al. West Nile premembrane-envelope genetic vaccine encoded as a chimera containing the transmembrane and cytoplasmic domains of a lysosome-Associated membrane protein: Increased cellular concentration of the transgene product, targeting to the MHC II compartment, and enhanced neutralizing antibody response. Virology 2005;332(1): 66-77
74. Ramanathan MP, Kutzler MA, Kuo YC, et al. Coimmunization with an optimized IL15 plasmid adjuvant enhances humoral immunity via stimulating B cells induced by genetically engineered DNA vaccines expressing consensus JEV and WNV E DIII. Vaccine 2009;27(32):4370-80
75. Seregin A, Nistler R, Borisevich V, et al. Immunogenicity of West Nile virus infectious DNA and its noninfectious derivatives. Virology 2006;356(1-2):115-25
76. Chang DC, Liu WJ, Anraku I, et al. Single-round infectious particles enhance immunogenicity of a DNA vaccine against West Nile virus. Nat Biotechnol 2008; 26(5):571-7
77. Hall RA, Nisbet DJ, Pham KB, et al. DNA vaccine coding for the full-length infectious Kunjin virus RNA protects mice against the New York strain of West Nile virus. Proc Natl Acad Sci USA 2003; 100(18):10460-4
78. Monath TP, Liu J, Kanesa-Thasan N, et al. A live, attenuated recombinant West Nile virus vaccine. Proc Natl Acad Sci USA 2006;103(17):6694-9
79. Arroyo J, Miller C, Catalan J, et al. ChimeriVax-West Nile virus live-Attenuated vaccine: Preclinical evaluation of safety, immunogenicity, and efficacy. J Virol 2004; 78(22):12497-507
80. Tesh RB, Arroyo J, Travassos Da Rosa AP, et al. Efficacy of killed virus vaccine, live attenuated chimeric virus vaccine, and passive immunization for prevention of West Nile virus encephalitis in hamster model. Emerg Infect Dis 2002;8(12):1392-7
81. Guy B, Guirakhoo F, Barban V, et al. Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. Vaccine 2010;28(3):632-49
82. Long MT, Gibbs EP, Mellencamp MW, et al. Efficacy, duration, and onset of immunogenicity of a West Nile virus vaccine, live Flavivirus chimera, in horses with a clinical disease challenge model. Equine Vet J 2007;39(6):491-7
83. Whitehead B. Updated recall notice PreveNile-West Nile Vaccine. Intervet Schering-Plough Animal Health. 2010
84. Pletnev AG, Claire MS, Elkins R, et al. Molecularly engineered live-Attenuated chimeric West Nile/dengue virus vaccines protect rhesus monkeys from West Nile virus. Virology 2003;314(1):190-5
85. Pletnev AG, Swayne DE, Speicher J, et al. Chimeric West Nile/dengue virus vaccine candidate: Preclinical evaluation in mice, geese and monkeys for safety and immunogenicity. Vaccine 2006;24(40-41): 6392-404
86. Karaca K, Bowen R, Austgen LE, et al. Recombinant canarypox vectored West Nile virus (WNV) vaccine protects dogs and cats against a mosquito WNV challenge. Vaccine 2005;23(29):3808-13
87. Siger L, Bowen RA, Karaca K, et al. Assessment of the efficacy of a single dose of a recombinant vaccine against West Nile virus in response to natural challenge with West Nile virus-infected mosquitoes in horses. Am J Vet Res 2004;65(11):1459-62
88. Iglesias MC, Frenkiel MP, Mollier K, et al. A single immunization with a minute dose of a lentiviral vector-based vaccine is highly effective at eliciting protective humoral immunity against West Nile virus. J Gene Med 2006;8(3):265-74
89. Coutant F, Frenkiel MP, Despres P, Charneau P. Protective antiviral immunity conferred by a nonintegrative lentiviral vector-based vaccine. PLoS ONE 2008; 3(12):e3973
90. Despres P, Combredet C, Frenkiel MP, et al. Live measles vaccine expressing the secreted form of the West Nile virus envelope glycoprotein protects against West Nile virus encephalitis. J Infect Dis 2005; 191(2):207-14
91. Brandler S, Marianneau P, Loth P, et al. Measles vaccine expressing the secreted form of West Nile virus envelope glycoprotein induces protective immunity in squirrel monkeys, a new model of West Nile virus infection. J Infect Dis 2012;206(2):212-19
92. Iyer AV, Pahar B, Boudreaux MJ, et al. Recombinant vesicular stomatitis virus-based west Nile vaccine elicits strong humoral and cellular immune responses and protects mice against lethal challenge with the virulent west Nile virus strain LSU-AR01. Vaccine 2009;27(6):893-903
93. Schepp-Berglind J, Luo M, Wang D, et al. Complex adenovirus-mediated expression of West Nile virus C, PreM, E, and NS1 proteins induces both humoral and cellular immune responses. Clin Vaccine Immunol 2007;14(9):1117-26
94. Lustig S, Olshevsky U, Ben-Nathan D, et al. A live attenuated West Nile virus strain as a potential veterinary vaccine. Viral Immunol 2000;13(4):401-10
95. Yamshchikov G, Borisevich V, Seregin A, et al. An attenuated West Nile prototype virus is highly immunogenic and protects against the deadly NY99 strain: A candidate for live WN vaccine development. Virology 2004;330(1):304-12
96. Whiteman MC, Li L, Wicker JA, et al. Development and characterization of non-glycosylated E and NS1 mutant viruses as a potential candidate vaccine for West Nile virus. Vaccine 2010;28(4):1075-83
97. Yu L, Robert Putnak J, Pletnev AG, Markoff L. Attenuated West Nile viruses bearing 3'SL and envelope gene substitution mutations. Vaccine 2008;26(47):5981-8
98. Liu WJ, Wang XJ, Clark DC, et al. A single amino acid substitution in the West Nile virus nonstructural protein NS2A disables its ability to inhibit alpha/beta interferon induction and attenuates virus virulence in mice. J Virol 2006;80(5): 2396-404
99. Wicker JA, Whiteman MC, Beasley DW, et al. A single amino acid substitution in the central portion of the West Nile virus NS4B protein confers a highly attenuated phenotype in mice. Virology 2006;349(2): 245-53
100. Widman DG, Ishikawa T, Fayzulin R, et al. Construction and characterization of a second-generation pseudoinfectious West Nile virus vaccine propagated using a new cultivation system. Vaccine 2008;26(22): 2762-71
101. Widman DG, Ishikawa T, Giavedoni LD, et al. Evaluation of RepliVAX WN, a single-cycle flavivirus vaccine, in a non-human primate model of West Nile virus infection. Am J Trop Med Hyg 2010; 82(6):1160-7
102. Ng T, Hathaway D, Jennings N, et al. Equine vaccine for West Nile virus. Dev Biol (Basel) 2003;114:221-7
103. Qiao M, Ashok M, Bernard KA, et al. Induction of sterilizing immunity against West Nile Virus (WNV), by immunization with WNV-like particles produced in insect cells. J Infect Dis 2004;190(12):2104-8
104. Diamond MS, Pierson TC, Fremont DH. The structural immunology of antibody protection against West Nile virus. Immunol Rev 2008;225:212-25
105. Chu JH, Chiang CC, Ng ML. Immunization of flavivirus West Nile recombinant envelope domain III protein induced specific immune response and protection against West Nile virus infection. J Immunol 2007;178(5):2699-705
106. Throsby M, Geuijen C, Goudsmit J, et al. Isolation and characterization of human monoclonal antibodies from individuals infected with West Nile Virus. J Virol 2006;80(14):6982-92
107. Vogt MR, Moesker B, Goudsmit J, et al. Human monoclonal antibodies against West Nile virus induced by natural infection neutralize at a postattachment step. J Virol 2009;83(13):6494-507
108. Oliphant T, Nybakken GE, Austin SK, et al. Induction of epitope-specific neutralizing antibodies against West Nile virus. J Virol 2007;81(21):11828-39
109. Diamond MS, Mehlhop E, Oliphant T, Samuel MA. The host immunologic response to West Nile encephalitis virus. Front Biosci (Landmark Ed) 2009;14: 3024-34
110. Suthar MS, Diamond MS, Gale M Jr. West Nile virus infection and immunity. Nat Rev Microbiol 2013;11(2):115-28
111. Spohn G, Jennings GT, Martina BE, et al. A VLP-based vaccine targeting domain III of the West Nile virus E protein protects from lethal infection in mice. Virol J 2010;7:146
112. Chua AJ, Vituret C, Tan ML, et al. A novel platform for virus-like particledisplay of flaviviral envelope domain III: Induction of Dengue and West Nile virus neutralizing antibodies. Virol J 2013;10:129
113. Magnusson SE, Karlsson KH, Reimer JM, et al. Matrix-M adjuvanted envelope protein vaccine protects against lethal lineage 1 and 2 West Nile virus infection in mice. Vaccine 2014;32(7):800-8
114. Cox RJ, Pedersen G, Madhun AS, et al. Evaluation of a virosomal H5N1 vaccine formulated with Matrix M adjuvant in a phase I clinical trial. Vaccine 2011;29(45): 8049-59
115. Watts DM, Tesh RB, Siirin M, et al. Efficacy and durability of a recombinant subunit West Nile vaccine candidate in protecting hamsters from West Nile encephalitis. Vaccine 2007;25(15):2913-18
116. Monath TP, McCarthy K, Bedford P, et al. Clinical proof of principle for ChimeriVax: Recombinant live, attenuated vaccines against flavivirus infections. Vaccine 2002;20(7-8): 1004-18
117. Guirakhoo F, Kitchener S, Morrison D, et al. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: Effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. Hum Vaccin 2006;2(2): 60-7
118. Miller JD, van der Most RG, Akondy RS, et al. Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. Immunity 2008;28(5):710-22
119. Akondy RS, Monson ND, Miller JD, et al. The yellow fever virus vaccine induces a broad and polyfunctional human memory CD8+ T cell response. J Immunol 2009; 183(12):7919-30
120. James EA, LaFond RE, Gates TJ, et al. Yellow fever vaccination elicits broad functional CD4+ T cell responses that recognize structural and nonstructural proteins. J Virol 2013;87(23):12794-804
121. Blom K, Braun M, Ivarsson MA, et al. Temporal dynamics of the primary human T cell response to yellow fever virus 17D as it matures from an effector-To a memory-Type response. J Immunol 2013; 190(5):2150-8
122. Samina I, Havenga M, Koudstaal W, et al. Safety and efficacy in geese of a PER.C6-based inactivated West Nile virus vaccine. Vaccine 2007;25(49):8338-45
123. Lim CK, Takasaki T, Kotaki A, Kurane I. Vero cell-derived inactivated West Nile (WN) vaccine induces protective immunity against lethal WN virus infection in mice and shows a facilitated neutralizing antibody response in mice previously immunized with Japanese encephalitis vaccine. Virology 2008;374(1):60-70
124. Orlinger KK, Holzer GW, Schwaiger J, et al. An inactivated West Nile Virus vaccine derived from a chemically synthesized cDNA system. Vaccine 2010; 28(19):3318-24
125. Brown F. Review of accidents caused by incomplete inactivation of viruses. Dev Biol Stand 1993;81:103-7
126. Nathanson N, Langmuir AD. The cutter incident. Poliomyelitis following formaldehyde-inactivated poliovirus vaccination in the United States during the spring of 1955. I. Background. Am J Hyg 1963;78:16-28
127. Nathanson N, Langmuir AD. The cutter incident. Poliomyelitis following formaldehyde-inactivated poliovirus vaccination in the United States during the Spring of 1955. Ii. Relationship of Poliomyelitis to Cutter Vaccine. Am J Hyg 1963;78:29-60
128. Nathanson N, Langmuir AD. The cutter incident. Poliomyelitis following formaldehyde-inactivated poliovirus vaccination in the United States during the Spring of 1955. II. Relationship of poliomyelitis to Cutter vaccine. 1963. Am J Epidemiol 1995;142(2):109-40.discussion 1995;107-108
129. Thomassen YE, van 't Oever AG, van Oijen MG, et al. Next generation inactivated polio vaccine manufacturing to support post polio-eradication biosafety goals. PLoS ONE 2013;8(12):e83374
130. Amanna IJ, Raue HP, Slifka MK. Development of a new hydrogen peroxide-based vaccine platform. Nat Med 2012;18(6):974-9
131. Martin JE, Pierson TC, Hubka S, et al. A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial. J Infect Dis 2007;196(12):1732-40
132. Nelson S, Jost CA, Xu Q, et al. Maturation of West Nile virus modulates sensitivity to antibody-mediated neutralization. PLoS Pathog 2008;4(5):e1000060
133. Ledgerwood JE, Pierson TC, Hubka SA, et al. A West Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trial. J Infect Dis 2011;203(10):1396-404
134. Cranenburgh R. DNA vaccine delivery. BioPharm International, Supplement 2011; s12-18
135. Diamond MS. SpringerLink (Online service). West Nile encephalitis virus infection viral pathogenesis and the host immune response. In: Emerging infectious diseases of the 21st century. xix Springer; NY, USA: 2009. 485 p. 416
136. Petersen LR, Roehrig JT. Flavivirus DNA vaccines-good science, uncertain future. J Infect Dis 2007;196(12):1721-3
137. Sardesai NY, Weiner DB. Electroporation delivery of DNA vaccines: Prospects for success. Curr Opin Immunol 2011;23(3): 421-9
138. Durbin AP, Wright PF, Cox A, et al. The live attenuated chimeric vaccine rWN/DEN4Delta30 is well-Tolerated and immunogenic in healthy flavivirus-naive adult volunteers. Vaccine 2013;31(48): 5772-7
139. Biedenbender R, Bevilacqua J, Gregg AM, et al. Phase II, randomized, double-blind, placebo-controlled, multicenter study to investigate the immunogenicity and safety of a West Nile virus vaccine in healthy adults. J Infect Dis 2011;203(1):75-84
140. Dayan GH, Bevilacqua J, Coleman D, et al. Phase II, dose ranging study of the safety and immunogenicity of single dose West Nile vaccine in healthy adults /= 50 years of age. Vaccine 2012;30(47):6656-64
141. Guirakhoo F, Pugachev K, Arroyo J, et al. Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: Genetic reconstructions, dose adjustment, and antibody responses against wild-Type dengue virus isolates. Virology 2002;298(1):146-59
142. Monath TP, Levenbook I, Soike K, et al. Chimeric yellow fever virus 17D-Japanese encephalitis virus vaccine: Dose-response effectiveness and extended safety testing in rhesus monkeys. J Virol 2000;74(4): 1742-51
143. Dayan GH, Pugachev K, Bevilacqua J, et al. Preclinical and clinical development of a YFV 17 D-based chimeric vaccine against West Nile virus. Viruses 2013;5(12): 3048-70
144. Kaiser J. Public health. Outbreak pattern stymies vaccine work. Science 2012; 337(6098):1030
145. Durbin AP, Karron RA, Sun W, et al. Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region. Am J Trop Med Hyg 2001;65(5):405-13
146. Laassri M, Bidzhieva B, Speicher J, et al. Microarray hybridization for assessment of the genetic stability of chimeric West Nile/dengue 4 virus. J Med Virol 2011;83(5): 910-20
147. Monath TP, Guirakhoo F, Nichols R, et al. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): Phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen. J Infect Dis 2003;188(8):1213-30
148. Lieberman MM, Clements DE, Ogata S, et al. Preparation and immunogenic properties of a recombinant West Nile subunit vaccine. Vaccine 2007;25(3):414-23
149. Lieberman MM, Nerurkar VR, Luo H, et al. Immunogenicity and protective efficacy of a recombinant subunit West Nile virus vaccine in rhesus monkeys. Clin Vaccine Immunol 2009;16(9):1332-7
150. Coller BA, Pai V, Weeks-Levy C, Ogata S. United States patent application No. US20120141520 A1: Recombinant subunit West Nile virus vaccine for protection of human subjects. 2012
151. de Alwis R, Smith SA, Olivarez NP, et al. Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. Proc Natl Acad Sci USA 2012;109(19):7439-44
152. Wood DJ, Heath AB. Comparability of poliovirus neutralizing antibody tests. Biologicals 1992;20(4):293-300
153. Anderson SG, Skegg J. The international standard for anti-smallpox serum. Bull World Health Organ 1970;42(4):515-23
154. FDA. 2012. Countering Bioterrorism Questions and Answers [Online]. Available from: Www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/ ProductSecurity/ucm110322.htm [Last accessed 16 January 2014]
155. Burns DL. Licensure of vaccines using the Animal Rule. Curr Opin Virol 2012;2(3): 353-6
156. Halstead SB, Mahalingam S, Marovich MA, et al. Intrinsic antibody-dependent enhancement of microbial infection in macrophages: Disease regulation by immune complexes. Lancet Infect Dis 2010;10(10): 712-22
157. Thomas SJ, Endy TP. Critical issues in dengue vaccine development. Curr Opin Infect Dis 2011;24(5):442-50
158. Bentsi-Enchill AD, Schmitz J, Edelman R, et al. Long-Term safety assessment of live attenuated tetravalent dengue vaccines: Deliberations from a WHO technical consultation. Vaccine 2013;31(23):2603-9
159. Heinz FX, Stiasny K. Flaviviruses and flavivirus vaccines. Vaccine 2012;30(29): 4301-6
160. Halstead SB. Neutralization and antibody-dependent enhancement of dengue viruses. Adv Virus Res 2003;60:421-67
161. Vogt MR, Dowd KA, Engle M, et al. Poorly neutralizing cross-reactive antibodies against the fusion loop of West Nile virus envelope protein protect in vivo via Fcgamma receptor and complement-dependent effector mechanisms. J Virol 2011;85(22):11567-80
162. Sabchareon A, Wallace D, Sirivichayakul C, et al. Protective efficacy of the recombinant, live-Attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: A randomised, controlled phase 2b trial. Lancet 2012;380(9853):1559-67
163. Zohrabian A, Meltzer MI, Ratard R, et al. West Nile virus economic impact. Louisiana, 2002. Emerg Infect Dis 2004; 10(10):1736-44
164. Barber LM, Schleier JJ 3rd, Peterson RK. Economic cost analysis of West Nile virus outbreak, Sacramento County, California, USA, 2005. Emerg Infect Dis 2010;16(3): 480-6
165. Murray KO, Ruktanonchai D, Hesalroad D, et al. West Nile virus, Texas, USA, 2012. Emerg Infect Dis 2013;19(11):1836-8
166. Stephens DS, Ahmed R, Orenstein WA. Vaccines at what price? Vaccine 2014
167. Martina BE, Koraka P, Osterhaus AD. West Nile Virus: Is a vaccine needed? Curr Opin Investig Drugs 2010;11(2):139-46
168. USA Census Bureau. Available from: Www. census.gov
169. Petersen LR, Brault AC, Nasci RS. West Nile virus: Review of the literature. JAMA 2013;310(3):308-15
170. Wang T, Anderson JF, Magnarelli LA, et al. Immunization of mice against West Nile virus with recombinant envelope protein. J Immunol 2001;167(9):5273-7
171. Ledizet M, Kar K, Foellmer HG, et al. A recombinant envelope protein vaccine against West Nile virus. Vaccine 2005; 23(30):3915-24
172. Demento SL, Bonafe N, Cui W, et al. TLR9-Targeted biodegradable nanoparticles as immunization vectors protect against West Nile encephalitis. J Immunol 2010; 185(5):2989-97
173. Jarvi SI, Hu D, Misajon K, et al. Vaccination of captive nene (Branta sandvicensis) against West Nile virus using a protein-based vaccine (WN-80E). J Wildl Dis 2013;49(1):152-6
174. McDonald WF, Huleatt JW, Foellmer HG, et al. A West Nile virus recombinant protein vaccine that coactivates innate and adaptive immunity. J Infect Dis 2007; 195(11):1607-17
175. Gershoni-Yahalom O, Landes S, Kleiman-Shoval S, et al. Chimeric vaccine composed of viral peptide and mammalian heat-shock protein 60 peptide protects against West Nile virus challenge. Immunology 2010;130(4):527-35